Search for: [Abstract = "TRAIL\/Apo2L has been catching attention of many researchers focused on the development of cancer therapies since its discovery. The interest in the molecule results from the fact that almost from the very beginning it has been identified as a molecule capable of inducing apoptosis in cancer cells while maintaining safety against healthy cells. Thus, the discovery of TRAIL initiated the exploration of the concept of using Death Receptors in targeted therapies. So far, however, no company has managed to implement the novel drug based on that. The concept of \"enriching\" TRAIL analogues with domains exhibiting an additional, different than apoptosis, mechanism of action is currently being explored. One of the proposed solutions is to obtain fusions of recombinant Apo2L\/TRAIL and human interferon domains. The added value of such structures should be\: stimulation of immune system cells to fight cancer, targeted delivery of interferon, extension of t1\/2 of recombinant TRAIL and sensitization of cancer cells to TRAIL\-induced apoptosis. The recombinant TRAIL\-IFN fusion described in this study, shows a significant advantage over the recombinant human variant of TRAIL in most of the research models used – cytotoxic activity in vitro, mechanisms of cell death, cell cycle analysis, cell morphology, in vivo antitumor efficacy. However there may appear following problems in the further develo"]

Number of results: 1